Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.68 |
| ▸ | CDK1 | P06493 | 2/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.68 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.68 |
| ▸ | CDK2 | P24941 | 2/20 | 0.68 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.68 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.68 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 16/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939928 | 1.00 | CCNB2 (0.68) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL647417 | 0.98 | CCNB2 (0.66) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL3769079 | 0.97 | CCNB2 (0.64) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL970432 | 0.97 | CCNB2 (0.64) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Acetamide SCHEMBL28491482 | 0.92 | DYRK1A (0.64) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Propionamide SCHEMBL28500673 | 0.88 | DYRK1A (0.60) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6456554 | 0.87 | MAOA (0.61) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Butyramide SCHEMBL28501063 | 0.86 | DYRK1A (0.57) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Norharmane SCHEMBL1626892 | 0.85 | MAOA (0.63) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL15236149 | 0.83 | CCNB2 (0.71) | CCNB2CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 892 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | SINTALICA S R L (IT) | 2026-05-21 | — | — | US | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4638419-A1 | NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-10-29 | — | — | EP | claimed |
| EP-4601627-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4601655-A1 | DELIVERY SYSTEM FOR THE CONTROLLED RELEASE OF PSYCHEDELIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4601665-A1 | COMPOSITION COMPRISING TRYPTAMINES AND MAOIS COMPOUNDS SELECTED FROM ?-CARBOLINE INHIBITORS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4583856-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | Native Code Bio, LLC (US) | 2025-07-16 | — | — | EP | claimed |
| US-20250151728-A1 | ANTIMICROBIAL SYSTEM WITH BETA CARBOLINE ALKALOID AND INDOLE ALKALOID AND COMPOSITIONS COMPRISING THEM | CONOPCO, INC., D/B/A UNILEVER (US) | 2025-05-15 | — | — | US | claimed |
| US-20250099357-A1 | ANTIMICROBIAL SYSTEM WITH BETA CARBOLINE ALKALOID AND PHENOLIC ACID AND COMPOSITIONS COMPRISING THEM | CONOPCO, INC., D/B/A UNILEVER (US) | 2025-03-27 | — | — | US | claimed |
| WO-2024254645-A1 | COMPOSITION AND METHOD TO TREAT, AMELIORATE OR PREVENT A PSYCHOLOGICAL, NEUROLOGICAL OR INFLAMMATORY DISORDER, AND METHOD FOR PREPARING COMPOSITION | Psychae Therapeutics Pty Ltd (AU) | 2024-12-19 | — | — | WO | claimed |
| WO-2008112195-A1 | METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OR STABILIZATION OF FIBROSIS | BIOSEEK, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2006124003-A1 | COMPOSITE MALDI MATRIX MATERIAL AND METHODS OF USING IT AND KITS THEREOF IN MALDI | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-11-23 | — | — | WO | claimed |
| US-20060261267-A1 | Composite MALDI matrix material and methods of using it and kits thereof in MALDI | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2006-11-23 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0620918-B1 | CARBON DIOXIDE DETECTOR | JOHNSON & JOHNSON PROFESSIONAL (GB) | 1997-07-30 | — | — | EP | claimed |
| US-5591738-A | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof | NDA INTERNATIONAL, INC. (US) | 1997-01-07 | — | — | US | claimed |
| US-5480611-A | Carbon dioxide detector | GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC. | 1996-01-02 | — | — | US | claimed |
| EP-0620918-A1 | CARBON DIOXIDE DETECTOR. | JOHNSON & JOHNSON PROFESSIONAL (GB) | 1994-10-26 | — | — | EP | claimed |
| WO-1993014399-A1 | CARBON DIOXIDE DETECTOR | JOHNSON & JOHNSON PROFESSIONAL PRODUCTS LTD. (GB) | 1993-07-22 | — | — | WO | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099357-A1 | ANTIMICROBIAL SYSTEM WITH BETA CARBOLINE ALKALOID AND PHENOLIC ACID AND COMPOSITIONS COMPRISING THEM | DBH, CGAS, MAVS | CCNB2 2050/4885CDK1 2736/4885CCNB1 2432/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | CCNB2 1542/4885CDK1 1668/4885CCNB1 929/4885 |
| US-20250151728-A1 | ANTIMICROBIAL SYSTEM WITH BETA CARBOLINE ALKALOID AND INDOLE ALKALOID AND COMPOSITIONS COMPRISING THEM | IDO1, IDO2, MAVS | CCNB2 2370/4885CDK1 3006/4885CCNB1 2648/4885 |
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | HTR2B, BDNF, HTR3B | CCNB2 593/4885CDK1 270/4885CCNB1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.